CHICAGO–(BUSINESS WIRE)–Anju Software Inc., a life sciences software platform backed by Providence Equity Partners, has acquired the assets of ClinPlus, a division of DZS Software Solutions, Inc.
“ClinPlus has a full suite of products used for the performance of clinical trials including EDC, IWRS, CTMS, eTMF, Data Management, Coding and SAS Reporting. With this complete product suite, Anju can provide full clinical trial software support from Phase 1 to Phase 4 with a scalable web platform for CROs and pharma companies,” said Kurien Jacob, CEO of Anju Software. Jacob also added that the acquisition of ClinPlus is consistent with Anju’s strategy of continuing to enhance its product offering through acquisitions and internal development.
“Anju will accelerate the growth of ClinPlus as part of their overall consolidation and growth strategy which is at a stage where the additional resources that Anju can provide are essential,” said Doron Steger, President of DZS.
“We are pleased with the execution of the growth strategy of Anju with ClinPlus being the third acquisition in a year. After having established a dominant position in Medical Affairs with the acquisition of OBA and OpenIQ, ClinPlus will enable Anju to enter and grow in the clinical trial space,” according to Gopi Vaddi, Managing Director of Providence Strategic Growth Fund.
About Anju Software
Anju Software is a life sciences enterprise software platform focused on delivering exceptional business application solutions with outstanding customer support. Anju was founded by a group of operating and investment professionals with deep software domain expertise and a proven track record of building software platforms through strategic acquisitions and organic growth. In 2016, Anju acquired Online Business Applications (OBA), which is the market leader in providing medical information solutions to the pharmaceutical and CRO industries and acquired OpenQ in April 2017, a leader in Key Opinion Leader (KOL) management.
Anju Software is a portfolio company of Providence Strategic Growth, the growth equity affiliate of Providence Equity Partners, a global private equity firm with $50 billion in assets under management.
About DZS Software Solutions
DZS Software Solutions, Inc. is a privately held company founded in 1996 and providing clinical trials software to the biotech and pharmaceutical industry worldwide. DZS will retain DZS Clinical Services, a division of DZS Software Solutions, which is a full service CRO having supported numerous drug approvals, conducted hundreds of clinical studies for both large and small pharmaceutical and biotech companies for a variety of clinical indications. DZS Clinical services use the ClinPlus product suite which is now part of Anju.
About Providence Equity
Providence is a premier, global asset management firm with $50 billion in assets under management across complementary private equity and credit businesses. Providence pioneered a sector focused approach to private equity investing with the vision that a dedicated team of industry experts could build exceptional companies of enduring value. Since the firm’s inception in 1989, Providence has invested in more than 150 companies and is the leading equity investment firm focused on the media, communications, education and information industries. Providence is headquartered in Providence, RI and also has offices in New York, London, Hong Kong, Singapore and New Delhi. For more information on Providence Equity, please visit www.provequity.com.
Snell and Wilmer acted as legal advisors to Anju and Madison Park Group acted as investment banking advisors to Anju on this transaction.
Kurien Jacob, 480-326-2358
DZS Software Solutions, Inc.
Greg Ambra / Doron Steger, 732-764-6969
Sard Verbinnen & Co
Andrew Cole / Patrick Scanlan, 212-687-8080